NCT01257594 2023-05-25
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Columbia University
Phase 1 Completed
Clinical Trials
13 trialsNCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00509431 2020-07-31
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed
NCT00187486 2017-09-05
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
University of California, San Francisco
Phase 2 Completed
NCT00301418 2016-02-10
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Northwell Health
Phase 1/2 Completed
NCT00525525 2014-11-14
AVF4120s
University of California, San Francisco
Phase 2 Completed
NCT00609999 2014-07-16
Ph I Dasatinib + Erlotinib in Recurrent MG
Duke University
Phase 1 Completed
NCT00672243 2013-08-07
Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme
Duke University
Phase 2 Completed
NCT00387894 2013-06-04
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
University of California, San Francisco
Phase 2 Terminated
NCT00671970 2013-05-13
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Duke University
Phase 2 Completed
NCT00274833 2012-12-06
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00227032 2012-03-06
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated